| |

Predicting How a Patient Will Respond to Mesothelioma Treatment

ByHolly Zink

Predicting How a Patient Will Respond to Mesothelioma Treatment

Malignant pleural mesothelioma is a rare cancer. Early diagnosis is challenging. Treatments are the first clinical option in the advanced disease stage.

A doctor’s initial clinical response says a lot about the patient’s prognosis. It may even represent a useful way to identify patients with a better long-term outcome.

A new Italian study from the Journal of Clinical Medicine looks at this possibility.

First Mesothelioma Treatment Response Options

Scientists looked at the initial treatment response in 46 mesothelioma patients who had pleural mesothelioma. None of these patients had surgery as an option because their tumors were considered inoperable.

The doctor’s initial treatment response included a CT scan and clinical examination. This examination was usually after 2–3 cycles of drug therapy.

One treatment option is anti-angiogenic drugs. These treatments stop cancer tumors from growing their own blood vessels. A second treatment option is immunotherapy. This is a type of cancer treatment that helps your immune system fight cancer.

Patients treated with anti-angiogenic drugs or immunotherapy had a better initial treatment response. They were compared to patients only treated with standard chemotherapy.

Predicting a Patient’s Response to a Specific Treatment

For most patients, the disease diagnosis is late and at an advanced stage. This limits the number and types of treatments that are likely to work.

There are many new clinical trials in mesothelioma, but doctors need more information on how to select the best treatment option. For example, it would be helpful if doctors could predict how a patient will respond to each treatment option. There are several predictive factors of treatment options for mesothelioma. But none are very useful in the initial first treatment response.

Artificial Intelligence and Treatment Options

This new study found that patients treated with chemotherapy and innovative treatments had better results. But, the study went further than that.  It wanted to find out if a machine learning or artificial intelligence approach could support doctors’ decision-making. The study concluded that more research is needed into this promising idea.

Using artificial intelligence is an important tool for doctors now and in the future. Studies such as these will help clinicians develop ways to match each patient with the best treatment available for them.

Source

Massafra, Raffaella, Annamaria Catino, Pia Maria Soccorsa Perrotti, Pamela Pizzutilo, Annarita Fanizzi, Michele Montrone, and Domenico Galetta. “Informative Power Evaluation of Clinical Parameters to Predict Initial Therapeutic Response in Patients with Advanced Pleural Mesothelioma: A Machine Learning Approach.” Journal of Clinical Medicine 11, no. 6 (2022): 1659. https://doi.org/10.3390/jcm11061659

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…